key: cord-0703627-0zqkwvct
authors: Begum, Jubeda; Mir, Nasir Akbar; Dev, Kapil; Buyamayum, Bidyarani; Wani, Mohd Yaqoob; Raza, Meesam
title: Challenges and prospects of COVID‐19 vaccine development based on the progress made in SARS and MERS vaccine development
date: 2020-08-20
journal: Transbound Emerg Dis
DOI: 10.1111/tbed.13804
sha: b4a0565e3e7a5a6a9588f139d78291dab32fcbdd
doc_id: 703627
cord_uid: 0zqkwvct

The outbreak of COVID‐19 as a pandemic has shaken the global health system and economy by their roots. This epidemic is still spreading and showing no signs of decreasing trend. Vaccination could be the only effective and economical means to control this pandemic. A number of research institutions and pharmaceutical companies have plunged into the race of vaccine development against COVID‐19 which are in various stages of development. An intriguing fact of coronavirus infections is that in every decade of 21(st) century there is a new major coronavirus epidemic viz. SARS in 2002, MERS in 2012, and now COVID‐19; and such epidemics are expected in future too. Since, maximum biological characteristics of SARS‐CoV‐2 are still obscure, the scientists are relying on the information available on SARS‐CoV and to some extent on MERS‐CoV for designing and development of COVID‐19 vaccines. But there is a need of vigorous testing for immunogenicity, safety, efficacy, and level of protection conferred in the hosts. This review focuses on the challenges and prospects of vaccine development against COVID‐19. It highlights seriousness, bottlenecks in vaccine development, possible vaccine candidates, different vaccine strategies, safety evaluation issues, and vaccine production process pertaining to COVID‐19 based on the knowledge acquired on SARS and MERS vaccine development in the past.

The outbreak of rapidly spreading severe respiratory disease caused by novel coronavirus (CoV) in December of 2019 in Wuhan, China has put whole world on high alert. The World Health Organization (WHO) named it COVID-19 and declared it a global pandemic on 30 th January 2020 (Kim et al., 2020) . The disease has spread to more than 200 countries with over 5.12 million cases and more than 0.33 million deaths worldwide by 21 st May 2020 (Worldometer, 2020) . These numbers are still increasing rapidly. The normal life has been disrupted as a result of mandatory lockdowns, isolations, and quarantines in response to COVID-19 pandemic and has imposed a serious challenge to global health system and economy (Gorbalenya et al., 2020; Kupferschmidt et al., 2020) . The coronaviruses represent an ongoing as well as future threat to human health because of their wide distribution, higher prevalence, higher recombination potential of their genomes, profound genetic diversity, and increasing human-animal interaction (Hui et al., 2020; Zhu et al., 2020) . SARS-CoV-2 is relatively a large virus of betacoronavirus genus containing a single-stranded positive-sense RNA genome encapsulated within a membrane envelope (Morse et al., 2020) . It is one of the seven discrete coronavirus species capable of causing disease in humans (Zhu et al., 2020) . The Coronavirus Study Group (CSG) of International Committee on Taxonomy of Viruses (ICTV) changed its name from 2019-nCoV to SARS-CoV-2 because it was found to be related to severe acute respiratory syndrome coronavirus (SARS-CoV) after genomic analysis (Gorbalenya et al., 2020) . The genomic analysis revealed that SARS-CoV-2 genome is more closely related to bat RaTG13 SARS-CoV (96%) in particular and SARS-CoV (80%) in general compared to middle east respiratory syndrome (MERS) CoV (54%) genome (Zhou et al., 2020) .

The genomic analysis reveals similarities in receptor-binding motif of SARS-CoV-2 and SARS-CoV which directly binds human receptor protein called angiotensin-converting enzyme-2 (ACE-2) to enter target cells. This has direct bearing on its vaccine design, rapidity of vaccine development, and prediction of its pandemic potential (Kim et al., 2020) . Similar to SARS-CoV and MERS-CoV, the predilection site of SARS-CoV-2 is lower respiratory system and viral pneumonia occurs. However, SARS-CoV-2 may also attack gastrointestinal tract, heart, kidney, liver, and central nervous system resulting in death due to multiple organ failure (Zhu et al., 2019) .

Though, the exact reservoir of SARS-CoV-2 could not be established yet with surety, its humanto-human transmission is now well established, and the verified cases are growing at an alarming rate. After crossing the species barrier, within a month human to human transmission became responsible for widespread and rapid dissemination of virus across the entire population of China

This article is protected by copyright. All rights reserved with no pre-existing immunity Wu et al., 2020) . The current ferocious spread of indicates that SARS-CoV-2 is more transmissible or contagious than SARS-and MERS-CoVs (Cascella et al., 2020) . This grim situation of COVID-19 demands the generation of targeted vaccines and therapies for reducing the associated morbidity and mortality. However, the risk of contracting COVID-19 is highest in healthcare workers, elderly people over 60 years of age, and people suffering from diabetes and hypertension . Thus, these people need to be prioritized for vaccine trials and licensure .

The development of vaccine against SARS-CoV-2 to contain its spread and help eliminating it from human population is a challenging task because there is lack of information on its biological properties, epidemiology, specific immune responses against it, etc. (Ahmed et al., 2020) . There were 2494 laboratory-confirmed cases of MERS in 27 countries with 858 deaths (fatality rate 34.4%) and 8098 cases of SARS in 29 countries with 774 deaths (fatality rate ∼10%) globally (Zaki et al., 2012) . However, COVID-19 brought whole world to stand still because its transmissibility is much ferocious compared to MERS-and SARS-CoVs which has infected more than 5.12 million people including more than 0.33 million deaths globally with ∼6.5% fatality rate by 20 th May 2020 (Worldometer, 2020) . Another problematic aspect of SARS-CoV infections is the presence of non-structural protein 'papain-like protease' which behaves like a deubiquitinase and may deubiquinate certain host cell proteins such as interferon factor-3 and nuclear factor kappa B, resulting in immune suppression (Baez-Santos et al., 2015) . The potential of transmissibility or spread of viruses is measured in terms of reproductive number (R0). The stochastic and statistical methods have revealed an average R0 of 3.28 for SARS-CoV-2 which exceeds the WHO estimates of 1.4 to 2.5 (Morse et al., 2020) . However, the transmissibility of SARS CoV and MERS CoV under hospital setting is comparatively lesser which is indicated by their lower (less than 1) R0 values (Chowell et al., 2015) . It means a COVID-19 infected person can transmit the virus to 3.28 other persons, whereas SARS and MERS infected persons can transmit the virus to less than one other person. About 50% of the COVID-19 cases do not show signs of fever before hospitalization (Guan et al., 2020) . Higher R0 value of SARS-CoV-2 along with the transmission from asymptomatic infected individuals (Rothe et al., 2020) indicates that control and prevention of COVID-19 will be challenging without development of a vaccine (Bai et al., 2020; .

This article is protected by copyright. All rights reserved

The ability of SARS-CoV-2 to mutate is fairly inconclusive. Point mutations were found to be insufficient to create a new virus. According to two recent independent studies in Italy at the "Lazzaro Spallanzani" National Institute for Infectious Diseases (IRCCS) in Rome and the Forensic Division of the Department of Biomedical Sciences and Public Health (DSBSP) at Ancona University Hospital, the genetic sequencing of the virus samples taken from Italian and Chinese patients revealed very small and insignificant variations (Etherington, 2020) . This is an indication that the SARS-CoV-2 remains fairly stable during the course of transmission across multiple individuals and populations. Thus, a vaccine, whenever it arrives, will potentially be effective broadly and for a considerable time of few years at a time (Etherington, 2020) . Although, no recombination events were detected in SARS-CoV-2 yet , two coronaviruses co-infecting the same host can make one acquire a genomic fragment of hundreds or thousands base-pair long by recombination which enables the virus to increase its ecological niche or make the leap to a new species (Gralinski et al., 2015) . This recombination property of coronaviruses can be the reason for the emergence of SARS-CoV, MERS CoV, and now SARS-CoV-2 since 2002 (Chen, 2020). In a recent study 149 sites of mutations observed across the genome of 103 sequenced strains of SARS-CoV-2 resulted in two subtypes -L and S subtype. Significant differences in geographical distribution, transmission ability, and severity of disease were observed between the two subtypes, which potentially creates further hindrances in vaccine design . Another study provides a direct evidence that mutations currently occurring in the SARS-CoV-2 genome have functional potential to impact the viral pathogenicity .

In the past decade a number of sporadic efforts have been made to develop vaccines against human CoVs, but lack of cross-protection rendered by these vaccines due to their extensive sequence diversity has thwarted the progress (Graham et al., 2013) . Also, there is the possibility of transmission of SARS-CoV or SARS-CoV-2 from animal reservoirs. Thus, the concentration of focus on additional structural proteins, other than spike (S) protein, and conserved epitopes is needed to develop a vaccine which can induce broader heterologous and cross-protective immunity against CoVs within beta-CoV lineage (Saif, 2020) . Elucidation of the biological characteristics of any newly emerged virus is instrumental in establishing potential treatments and preventive strategies (Gillim-Ross and Subbarao, 2006) . The detailed biological characteristics of SARS-CoV-2 is still unknown and whether it infects only respiratory tract or both respiratory and

This article is protected by copyright. All rights reserved intestinal tracts is yet to be established. In the latter case oro-nasal vaccine followed by parenteral S protein based booster strategy can be optimum to prevent respiratory and enteric infections along with cessation of fecal and nasal shedding of viruses (Saif, 2020) . Another important aspect of biological characteristics of SARS-CoV-2 is the route of dissemination to lungs which is not clear yet. If the lungs get targeted after an upper respiratory tract infection then intranasal live or attenuated vaccine can effectively induce local immunity which could protect the upper as well as lower respiratory tracts and reduce nasal shedding. However, if the lungs are infected via viraemia, then parental vaccine can effectively elicit sufficient virus neutralizing (VN) antibodies in serum to block viraemia which in turn prevents lung infection and virus shedding (Saif, 2020) .

Furthermore, contributions of cytopathic effect of the virus and immunopathology in the pathogenesis of SARS-CoV infections is unclear which has a direct bearing on the vaccine strategy to be adopted for better protection (Gillim-Ross and Subbarao, 2006) . The undesired immunopotentiation in the form of eosinophilic infiltration or increased infectivity was observed following challenge infections after immunizations with whole virus vaccines or even complete spike protein vaccines (Jiang et al., 2012) . This constitutes another major obstacle in the development of SARS CoV vaccines.

Though, the vaccine candidates induce serum VN antibodies and systemic cell-mediated immune response in animal models, the correlates of immunity to COVID-19 in humans are still unknown (Saif, 2020) . However, in face of the ongoing COVID-19 epidemic vaccine development can be initiated in absence of knowledge on the correlates of immunity by utilizing the strategies developed for vaccine targeting of other viruses. It is because both mucosal and humoral immunity confers protection against most of the respiratory viral infections; however, the role of cell mediated immunity in such protection has not been established yet (Gillim-Ross and Subbarao, 2006) . Antibody dependent enhancement (ADE) of CoV infections following vaccination is also a major concern for vaccine development against COVID-19. Though, the mechanism behind ADE

is not yet clear this is supposed to be due to sub-neutralizing antibodies which do not have the capacity to completely neutralize viral particles but instead cause enhanced uptake and spread of the viruses by entering Fc receptor expressing cells (Wan et al., 2020; Gillim-Ross and Subbarao, 2006 ). Currently we do not have any approved treatment or vaccine against the deadly infections of CoVs, including COVID-19 because of lack of interest among pharmaceutical companies and lack of sustained government funding for vaccine development due to disappearance of SARS and decline of MERS (Cyranoski et al., 2020; Saif, 2020) . Compared to the traditional childhood and

This article is protected by copyright. All rights reserved adult vaccines, the development of vaccines against SARS CoVs for global health security or biodefense are considered less profitable and it has also been the major reason for the lack of interest shown by major multi-national pharmaceutical companies for commercial vaccine development . The outbreak scenarios are generally short lived and the proportion of people affected is small which does not constitute a significant vaccine market.

Furthermore, by the time a new vaccine is available, there might not be any patients available for clinical trials and also no significant market (Dhama et al., 2020) . The possible vaccine for COVID-19 must be made available for potential stockpiling because it may not be available for the current pandemic (Chen et al., 2020). However, extensive geographical spread and involvement of large number of people with rapidly increasing cases have sensitized the governments and pharmaceutical companies worldwide to reinforce their efforts against the control of COVID-19. Another aspect of COVID-19 infection is nasal shedding of virus and further transmission in the population which can't be prevented without mucosal immunity. The possible vaccine should not only prevent the deaths but also the nasal virus shedding by boosting mucosal immunity which is generally short-lived and requires multiple booster vaccinations (Saif, 2020) . Another bottleneck in the process of vaccine development against COVID-19 is the lack of suitable animal model to test the vaccine efficacy and safety. None of the animal models appropriately mimic the human COVID-19 infection and the potential correlates of infection (Saif, 2020) . Though, ferrets mimic the SARS pathogenesis well in humans (Roper and Rehm, 2009) their limitation is the less well characterised immune system. On the other hand if SARS susceptible pigs are susceptible to SARS-CoV-2 too, they are supposed to be potentially better model because of their close resemblance to humans in terms of their outbred nature, physiology, metabolism, respiratory system, and immune responses (Vlasova et al., 2016) .

Since the SARS-CoV-2 shares a considerable genetic sequence homology and sequence identity of various essential enzymes with SARS-CoV (Hui et al., 2020; Zhu et al., 2020; Perlman 2020; Zhou et al., 2020) , the vaccine strategies already built for SARS could potentially facilitate the early design of COVID-19 vaccine (Morse et al., 2020; . Both SARS-CoV-2 and SARS-CoV bind to similar ACE2 receptors of human lungs (Hoffmann et al., 2020; Zhou et al., 2020) . Similar to other CoVs, genome of SARS-CoV-2 translates four major structural proteins viz. nucleocapsid protein (N), spike glycoprotein (S), membrane glycoprotein (M), and envelop protein (E) (Saif, 2020) . The S protein is the major focus in vaccine development because it

This article is protected by copyright. All rights reserved contains receptor binding domain (RBD), functions in viral attachment via S1 subunit, fuses with host cell via S2 subunit, and strongly induces VN antibodies which blocks binding with the host receptor cells in lungs (Zhou et al., 2020) . However, M protein has the ability to induce VN antibodies and N protein contains T-cell epitopes in SARS-CoV, which means they can also act as an efficient vaccine targets (Rauch et al., 2018; Roper and Rehm 2009; Enjuanes et al., 2008) .

The elements of virus particles, including proteins, lipids, polysaccharides, nucleic acids, and other associated components, constitute whole cell antigens (WCA) . The development of killed and live-attenuated vaccines present the whole cell antigens to elicit immune response (Minor et al., 2015) . In this regard virus strains of SARS-CoV-2 have been successfully isolated by many institutions globally for development of killed or live-attenuated whole cell vaccine . However, it is unavoidable to face more difficulties in quality control and consistency evaluation of such vaccines because of complex compositions antigens and such vaccines require stringent screening and testing for obtaining strains with certified safety (Marohn and Barry, 2013) . For example, a mutation (Y6398H) has been introduced into the Orf1a/b polyprotein (p59/nsp14/ExoN) which completely attenuated the virulence of mouse coronavirus (MHV-A59) and MHV-A59 vaccine significantly reduced virus replication in mice at day five following intracerebral inoculation (Morse et al., 2020) .

The S protein is the most promising antigen for production of SARS-CoV-2 vaccine. It is a surface protein directly recognized by host immune system . It mediates virus binding with ACE2 receptor in human lungs which is an essential step for virus fusion and entry into host cell to establish subsequent pathogenicity in lungs Lan et al., 2020) . Also, the S protein based vaccines developed against SARS-CoV and MERS-CoV were found to be effective to a large extent (Zhou et al., 2018; . The S protein in SARS-CoV-2 is cleaved into amino-terminal S1 and carboxy-terminal S2 subunits which is not the case with SARS-CoV (Saif, 2020) . The S1 subunit is further composed of two domains; N-terminal domain (NTD) and C-terminal domain (CTD). RBD is located in the CTD and S2 subunit contains the basic elements required for membrane fusion . The full length S protein and its antigenic components have the potential to serve as important candidates for vaccine development against COVID-19 (Jiaming et al., 2017; Zhou et al., 2018) . Though, the comparison of full length S protein sequences of SARS-CoV-2 and SARS-CoV revealed maximum variability in S1 subunit

This article is protected by copyright. All rights reserved of S protein, it is still a promising target for vaccine development against COVID-19 (Yu et al., 2020; Morse et al., 2020) .

The native S proteins exist as a trimeric form on the surface of virus. However, when its ectodomain or S1 is expressed as a recombinant protein in eukaryotic systems, the protein exists predominantly in a monomeric form (Li et al., 2013; Kim et al., 2020) . Recreating the trimeric structure has been shown to increase immunogenicity which depicts the importance of mimicking the native trimeric structure (Li et al., 2013; Krammer et al., 2012; Kim et al., 2020) . Using its patented Trimer-Tag © technology, Clover Biopharmaceuticals produced a COVID-19 S-Trimer subunit vaccine by a rapid mammalian cell-culture based expression system which resembles the native trimeric viral spike. Having extensive commercial-scale GMP biomanufacturing capabilities in China, Clover is expected to rapidly scale-up and produce large-quantities of this new coronavirus vaccine having GSK2 adjuvant Glaxo Smit Kline, 2020; . Based on their experience with MERS and SARS, Novavax developed their COVID-19 candidate vaccine targeting the S protein of SARS-CoV-2 by using their recombinant nanoparticle vaccine technology along with their proprietary adjuvant Matrix-MTM (Novavax, 2020). After single shot immunization high immunogenicity was exhibited in animal models with significant display of S protein-specific antibodies, antibodies blocking the binding of S protein to the receptor, and wild-type VN antibodies. First human trial was expected by mid-May.

A SARS coronavirus vaccine based on a recombinant full-length trimeric S protein exhibited native antigenicity, specific binding to soluble ACE2 receptor, adequate protection against challenge infection in animal model (Morse et al., 2020) . The vaccines based on fulllength S protein are supposed to present the correct conformation of the protein, provide more epitopes, and exhibit higher immunogenicity (Zhang et al., 2020) but in case of SARS-CoV some vaccines mediate enhancement of viral infection which has raised safety concerns over full-length S protein based vaccines (Jaume et al., 2012; . Furthermore, the S protein based subunit vaccines have been reported to produce higher VN antibody titers and better protection than live-attenuated SARS-CoV, full-length S protein, and DNA-based S protein vaccines (Buchholz et al., 2004; Morse et al., 2020) . However, mRNA vaccines put forward by Moderna are composed of mRNAs which encode for full-length S, S1, or S2 proteins from SARS-CoV and MERS-CoV and are carried in cationic lipid nanoparticles (Morse et al., 2020) . Higher VN antibody titers were observed in mice vaccinated with mRNA encoding full-length S protein compared to mRNA encoding S protein or S2 subunit and in New Zealand white rabbits full-

This article is protected by copyright. All rights reserved length S protein reduced more than 90% of viral load in lungs along with significant induction of VN antibody against MERS-CoV.

with the ACE2 receptor of host cells and immunization with RBD based vaccine blocks this interaction by inducing specific VN antibodies Zhou et al., 2019) . Since, these vaccines exert strong protective immunity against viral infection most of the COVID-19 subunit vaccines under process are based on RBD antigen . As a candidate for vaccine against SARS-CoV it has been demonstrated that RBD, consisting of multiple conformational neutralizing epitopes, induced higher VN antibody titer (Zhu et al., 2013) .

RBD of S protein is considered more suitable because it is relatively more conserved than the S1 subunit and contains multiple conformational neutralizing epitopes (Jiang et al., 2005; . However, S1 subunit itself induces strong immune response and protection against CoV infection (Li et al., 2013; Adney et al., 2019; . On the other hand, S2 subunit protein has conserved amino acid sequence and high homology among different virus strains which makes it a potential target for development of a broad spectrum vaccine effective against divergent virus strains (Elshabrawy et al., 2012; Zhou et al., 2018; .

Though, S2 subunit as well as NTD have the potential to elicit VN antibodies, they are less immunogenic, exhibit lower antibody titers, cellular immune responses, and protection compared to other antigenic determinants (Jiaming et al., 2017) . Thus, based on the above facts RBD and S1

protein are the critical vaccine candidates for SARS-CoV as well as SARS-CoV-2.

The N protein is highly conserved and most abundant protein in coronavirus which is actively involved in viral propagation (McBride et al., 2014) and is a potential additional target for the development of SARS and MERS vaccines. It is highly antigenic and induced specific humoral and cellular immune responses in convalescent-phase SARS patients (Leung et al., 2004) and C57BL/6 mice (Kim et al., 2004) . However, in contrast, it has been reported that it does not elicit VN antibodies to block virus binding the ACE2 receptor and prevent viral infection (Liu et al., 2006; Zheng et al., 2009) . Also, in hamsters N protein immunization did not induce VN antibodies and provided no protection against SARS-CoV (Buchholz et al., 2004) . These conflicting results suggest that N protein is not a reliable candidate for vaccine development for SARS-CoV but has a good diagnostic value because of its high immunogenicity (Zhang et al., 2020).

M protein is the most abundant and highly conserved trans-membrane glycoprotein on the surface of SARS-CoV involved in virus assembly (Neuman et al., 2011) . SARS-CoV M protein-derived peptides (M-131 and M-132-161), identified in sera of convalescent-phase SARS patients, have good immunogenicity to induce high titer of specific IgG antibody response in immunized rabbits (He et al., 2005a) . The full length M protein has been reported to elicit VN antibodies efficiently in SARS patients upon immunization (Pang et al., 2004) . The T cell epitope cluster containing domain of M protein has been reported to elicit a strong cellular immune response (Liu et al., 2010) . Though, this protein has not been investigated much for its protective efficacy against SARS-CoV infection, the above factors suggest its potential as a possible vaccine candidate against SARS-CoV-2.

The E protein is the smallest of the major structural proteins of CoVs. It is an important virulence factor and its knocking out has shown marked reduction of inflammatory factors IL-1, TNF, and IL-6 (Nieto-Torres et al., 2014). The potential B cell epitopes of the E protein of MERS-CoV are considered as probable vaccine protective targets which have the capacity to induce both T-cell and neutralizing antibody responses (Shi et al., 2015; Xie et al., 2018) . However, its immunogenicity is quite limited compared to other structural proteins (Zhang et al., 2020) and has been least investigated for vaccine development due to which it cannot considered as a suitable vaccine candidate for COVID-19.

Humoral immunity by B-cell antibodies and cellular immunity by T-cells are important for effective vaccines (Rappuoli et al., 2019) . On one hand, VN antibodies block the entry of viruses into human cells and on the other hand, cytotoxic CD8 T-cells and helper CD4 T-cells fully clear viruses from the infected cells (Fast and Chen, 2020). Researchers from the Hong Kong University of Science and Technology (HKUST) investigated the B-cell and T-cell S and N protein epitopes arising in response to SARS-CoV to find biomarkers that could be incorporated into vaccines to trigger an immune response against SARS-CoV-2 (Balfour, 2020) . Similar to SARS-CoV, the SARS-CoV-2 S protein is likely to be immunogenic which carries several T-cell and B-cell epitopes (Fast and Chen 2020). Since 23% and 16% of known SARS-CoV T-cell and B-cell epitopes mapped identically with that of SARS-CoV-2, respectively, and no mutations have been observed in these SARS-CoV-2 epitopes, harnessing the vaccine candidate value of these epitopes may offers a significant protection against COVID-19 (Ahmed et al., 2020) . Also, the

This article is protected by copyright. All rights reserved high genetic similarity between SARS-CoV-2 and SARS-CoV indicates that the vaccines developed for SARS-CoV may exhibit cross-reactivity with SARS-CoV-2 Dhama et al., 2020) . Profound antibody response has been generated against S protein in mouse models (Deming et al., 2006; Graham et al., 2012) and N protein in SARS-CoV infected patients . Though being effective, the antibody response developed in convalescent SARS patients was found to be short-lived in nature (Tang et al., 2011) .

However, compared to this humoral response, T-cell response against the structural proteins of SARS-CoV was found to be more dominant and provide long-term protection which makes the T-cell epitopes more interesting prospective vaccine candidate against SARS-CoV infections (Tang et al., 2011; Ng et al., 2016; . The potential of cross-reactivity among CoVs was confirmed in a study based on similarity in the T-cell epitopes of SARS-and MERS-CoVs which expounds the possibility of broad spectrum universal CoV vaccine . Additionally, Ahmed et al., (2020) argued that the prospects of T-cell epitopes in vaccine production against COVID-19 is more promising compared to B-cell epitopes. That is because of higher percentage of SARS-CoV derived T-cell epitopes that map identically with that of SARS-CoV-2, larger population expected to be covered, and long term protection conferred (Tang et al., 2011; Ng et al., 2016) . Furthermore, SARS-CoV derived antibodies targeting the RBD of S1 subunit of SARS-CoV-2 S protein may not be effective due to the large genetic mismatches observed in known structural epitopes targeting this domain Tian et al., 2020; Ahmed et al., 2020) .

Since, the SARS-CoV-2 reservoir has not been established yet, its re-emergence or the reemergence of its related virus in future is expected to infect the human populations again. Only the vaccine development targeting this virus will help contain the virus before it cripples the global health and economic system again as observed in the current pandemic. Currently, we do not have 

This article is protected by copyright. All rights reserved previous technological platforms, resource base, and demands imposed by the current pandemic.

The approaches and strategies adopted for SARS and MERS vaccines will provide intriguing inputs for the speedy design and development COVID-19 vaccines (Wang et al., 2020) . The use of new technologies like recombinant viral vectors and nucleic acid vaccines provide universal vaccine platforms which conveniently develop and present new antigenic targets from emerging viruses (Rauch et al., 2018) . Upon immunization they mimic attenuated virus vaccines which infects host cells and induce endogenously produced antigenic proteins, respectively, which elicit antibody as well as T-cell immune responses (Rauch et al., 2018; Roper and Rehm, 2009; Enjuanes et al., 2008; Schindewolf and Menachery 2019) . Most of the nucleic acid vaccines based on either DNA or mRNA constructs encode for S or RBD proteins in host cells (Roper and Rehm, 2009; Enjuanes et al., 2008; Schindewolf and Menachery 2019) and the similar proteins are prime targets of subunit vaccines for SARS-CoV and MERS-CoV which can be extended to SARS-CoV-2 too . Currently, most of the COVID-19 candidate vaccines under development are S protein or RBD subunit vaccines and vector vaccines which express mainly S protein or the RBD (WHO, 2020). The criteria for any successful vaccine development are safety, efficacy, and duration of immunity. However, in case of pandemics like COVID-19 rapid development of vaccine at a very high production capacity is another important criterion (Rauch et al., 2018) . When it comes to traditional inactivated and attenuated vaccines, the rapid production of such vaccines in large quantities under biosafety level-3 conditions is difficult which renders them less suitable as first-generation vaccines under pandemic conditions (Saif, 2020) .

Whole virus vaccines, either killed or live-attenuated, have multiple antigenic components which potentially induce wide variety of immunologic effectors in the host against virus (Sharma et al., 2011) . The reverse genetics mechanism is adopted to generate live attenuated CoV vaccines by deleting of key virulence factors. Such vaccines are immunologically highly efficient and exert wider cross protection which potentially induce mucosal, systemic, humoral, and cell mediated immunity upon immunization (Roper and Rehm, 2009; Enjuanes et al., 2008; Saif 2017; Schindewolf and Menachery 2019) . The inherent immunogenicity and ability of whole virus vaccines to stimulate toll-like receptors (TLRs) like TLR 3, TLR 7/8, and TLR 9 is their major advantage . These vaccines are considered most efficient in primary vaccination of naive hosts followed by parenteral booster vaccines for better protection (Saif, 2017) . This reverse genetic technique can be an ideal approach for successful development of attenuated

This article is protected by copyright. All rights reserved COVID-19 vaccine for priming immune responses in naive hosts followed by parenteral heterologous S or N protein booster vaccine to possibly elicit cross protection against strains within beta-CoV genus (Ng and Tan, 2017; Saif, 2020) . Earlier, -propriolactone inactivated SARS CoV whole-virus vaccine adjuvanted with MF59 elicited promising VN antibody titer in mice and got approval for human use in Europe (Stadler et al., 2005; Gillim-Ross and Subbarao, 2006) .

Globally, several institutions have successfully isolated the virus strains of SARS-CoV-2 and started research on the prospects of vaccine development . For example, Codagenix, Inc. collaborated with the Serum Institute of India, Ltd. to develop a live-attenuated vaccine against SARS-CoV-2 by "codon deoptimization technology" (Shieber, 2020) . Similarly,

Johnson & Johnson will attempt to deactivate SARS-CoV-2 which switches off its virulence factors but retains its ability to stimulate immune system. According to the company statement human trials are expected by September 2020 (Ryan, 2020) . Also, the researchers at University of Hong Kong developed a live influenza vaccine that expresses SARS-CoV-2 proteins (Cheung 2020). However, the development of live virus vaccines require propagation of high titers of infectious virus and extensive testing to ensure safety which warrants the requirement of biosafety level-3 for production (Gilim-Ross and Subbarao, 2006; . The ADE problem of CoV vaccines is particularly prominent with live or killed whole virus SARS coronavirus vaccines (Jiang et al., 2012; and incomplete inactivation of virus vaccine is a potential public health threat as well (Gillim-Ross and Subbarao, 2006) .

Subunit vaccines, safer and easier to produce, present one or few antigens to host with strong immunogenicity, but they require adjuvants to elicit a strong protective immune response . Subunit vaccines against SARS elicit immune response against the S protein which prevents binding of virus with ACE2 receptor in host lungs (Jiang et al., 2012) and currently, almost all RBD subunit vaccines in process of development against SARS-CoV-2 are based on S protein or RBD of S1 protein as antigens (WHO, 2020; . The SARS-CoV and SARS-CoV-2 RBDs present the similarity of over 80% in their amino acid sequence which offers an opportunity to develop either of the proteins as subunit vaccine for both and it also offer an advantage of minimum immunopotentiation in the host Jiang et al., 2012) .

After emergence of SARS in 2002, a subunit vaccine consisting of a soluble baculovirusexpressed NTD of S1 protein was developed and immunization in mice elicited high VN antibody

This article is protected by copyright. All rights reserved titers which conferred highly effective protection against subsequent intranasal challenge with SARS-CoV (Bisht et al., 2004) . At Baylor College of Medicine, Texas Children's Hospital Centre for Vaccine Development developed and tested a subunit vaccine based on the RBD of S1 protein of SARS-CoV which elicited a strong immunity on homologous virus challenge when formulated in alum (Jiang et al., 2012; Chen et al., 2017; Chen et al., 2014) . Although some full-length Sproteins of SARS have been observed to elicit increased infectivity and eosinophilic infiltration, Clover Biopharmaceuticals Inc. developed a trimerized S protein based subunit vaccine against SARS-CoV-2 using its Trimer-Tag © technology (Chen et al., 2020; Clover biopharmaceuticals, 2020). Also, Novavax Inc. is assessing the efficacy of its newly developed nanoparticle vaccine candidates based on S protein to arrive at a suitable vaccine candidate for future human trials 

As a result of tremendous advancement in biotechnology, mRNA vaccines represent a significant upgrade over conventional vaccine strategies owing to their higher potency, short production cycles, low-cost manufacturing, and safe administration (Pardi et al., 2018) . The sequential events in the process of mRNA vaccine development constitutes antigen selection, sequence analysis and optimization, screening of modified nucleotides, selection of delivery system, immune response and safety evaluation tests (Jahanafrooz et al., 2020) . A potential advantage of mRNA vaccines is the convenient availability of a portable mRNA 'printing' facility for the production of mRNA is large quantities (Saif, 2020) . The use of nanotechnology enhances the delivery of mRNA vaccine via intramuscular or intradermal route by using lipid nanoparticle coating (Rauch et al., 2018; Saif, 2020) . Thus, a number of major biotech companies have ventured into COVID-19 vaccine development using the advanced nucleic acid vaccine platforms, such Moderna and CureVac . Since, no mRNA vaccine has been licenced till date, its quality and safety testing may take more than the expected time . However, with advancement in nucleic acid technologies the nucleic acid vaccine performance in humans has improved due to new modifications and formulations and this approach is expected to ensure the first licenced 

A typical DNA vaccine is a plasmid DNA molecule which encodes for one or multiple antigens to be presented to the host immune system. They possess the advantages of stability and efficient delivery over mRNA vaccines but they possess the risk of vector mutations and integration into the host genome because they are required to enter the nucleus (Zhang et al., 2020; Liu 2019; Rauch et al., 2018) . DNA vaccines targeting the antigenic fragments such as S, N, M, and E proteins of SARS-CoV have been evaluated in mice (He et al., 2005b; Jin et al., 2005; Kim et al., 2004) and the DNA vaccines targeting S, M, and N proteins induced humoral as well as cellular immune response. However, variation in the level of immunity between the target proteins was observed (Jin et al., 2005 ). An approach of combining different vaccine strategies is considered superior in eliciting an efficient immune response and protection against SARS-CoV (Woo et al., 2005; Zakhartchouk et al., 2005) . For example, administration of S protein coding DNA vaccine, followed by whole virus inactivated vaccine or S peptide vaccine, elicited more powerful humoral and cell-mediated immune responses in mice than either type alone (Roper and Rehm, 2009; Enjuanes et al., 2008; Zakhartchouk et al., 2005; Woo et al., 2005) . The DNA vaccines are considered safe, stable, and can be produced rapidly but their immunogenicity and efficiency of eliciting immune response in humans has not been proven yet. The strategy of DNA vaccination was initiated in 1993 with promising results against influenza viruses but the same results could not be translated in humans yet . However, several biotech companies with advanced nucleic acid vaccine platforms, such as Inovio Pharmaceuticals, Applied DNA Sciences

This article is protected by copyright. All rights reserved Subsidiary, LineaRx, and Takis Biotech have taken up DNA vaccine development against COVID-19 (Chen et al., 2020; . There are two DNA vaccines under process of development against COVID-19. The DNA vaccine candidate, INO-4800, developed by Inovio Pharmaceuticals is in phase I clinical trials in the US and phase II clinical trials are expected this summer. Similarly, a linear DNA vaccine candidate against SARS-CoV-2, developed as result of collaboration between Applied DNA Science Subsidiary, LineaRx, and Takis Biotech, is in preclinical stage.

Live vector vaccines constitute the live viruses acting as vectors which express the desired heterologous antigens of targeted viruses. This vaccine strategy combines the strong immunogenicity property of live attenuated vaccines and the safety aspect of subunit vaccines, and this strategy is widely used to induce cellular immunity in host . Reverse genetics approach has been successfully used to develop live-attenuated viruses by inactivating exonuclease effects of non-structural protein 14 (nsp 14) or by deletion of the structural envelop protein in SARS-CoV (Graham et al., 2013) . By adopting the similar approach, H strain of avian infectious bronchitis virus (IBV) can be used to express the antigenic determinants of SARS-CoV and elicit humoral as well as cell-mediated immunity (Bijlenga, 2005; Dhama et al., 2020) . Thus, following safety evaluation in non-human primates, the recombinant avian IBV can act as a prospective vector vaccine for SARS-CoV-2 (Zhang and The recombinant adenovirus vectors of chimpanzee origin (CHAd63) have been used for development of SARS and MERS vaccines to overcome the widespread pre-existing immunity against human adenoviruses. The CHAd63 expresses SARS-CoV S or N protein or MERS-CoV S protein and was shown to confer different levels of protection in mice, ferret, and nonhuman primates following challenge (Roper and Rehm, 2009; Enjuanes et al., 2008; Schindewolf and Menachery, 2019) . The immunization of BALB/c mice with recombinant adenovirus vector

This article is protected by copyright. All rights reserved vaccine expressing MERS-CoV S protein induced systemic and mucosal antibodies along with memory T-cell response in lungs which indicates the potential of this vaccine to confer protection against MERS-CoV (Kim et al., 2019) . Other vectors for SARS and MERS vaccines which could be the prospective vectors for COVID-19 vaccines include modified vaccinia ankara (MVA), parainfluenza virus, measles virus, Newcastle disease virus, and vesicular stomatitis virus which have been shown to express S and/or N proteins of SARS-and MERS-CoV (Roper and Rehm, 2009; Enjuanes et al., 2008; Schindewolf and Menachery, 2019) . Even the use of Rabies virus as viral vector has shown promising results in BALB/c mice against MERS-CoV by expressing S protein of the same and eliciting higher levels of cellular immunity and earlier antibody response . After the outbreak of SARS in 2002, a live attenuated Chimeric bovine/human parainfluenza virus 3 (BHPIV3) was utilized as a vector for the expression of S, N, M, and E proteins of SARS-CoV. However, only vector vaccine expressing S protein was successful in providing protection against SARS in hamsters (Buchholz et al., 2004; Gillim-Ross and Subbarao, 2006) . Also, the vaccines expressing multiple proteins other than S protein could not provide protection to hamsters which suggests that only S protein is a promising antigen in vectored vaccines. On the other hand, vaccination of African green monkey by BHPIV3 vector expressing S protein of SARS-CoV conferred protection as well as prevented nasal virus shedding following challenge (Bukreyev et al., 2004) .

Safety is a major concern of vaccines which needs due consideration while development, otherwise, failure of approval by a regulating agency is a certified outcome of the process. The formalin and UV-inactivated SARS vaccine and -radiation inactivated MERS vaccine developed a peculiar eosinophil-related lung pathology in mice following challenge. But when toll-like receptor agonists were associated with SARS vaccine there was reduction in lung pathology (Roper and Rehm, 2009; Schindewolf and Menachery, 2019) . Another study with ferrets reported liver pathology following vaccination with modified vaccinia ankara (MVA) expressing S protein, however, no other studies supported such claims till date (Roper and Rehm, 2009 ). For COVID-19 vaccine development process S protein is the most targeted candidate antigen. Its biological characteristics, other than receptor binding and membrane fusion, are obscure which may potentially exert other biological activities affecting the vaccine safety and efficacy.

On the other hand, ADE is a long-term obstacle in the development of vaccines against CoVs.

This ADE has been observed with full-length S protein and is considered to be associated with the

This article is protected by copyright. All rights reserved production of S protein specific antibodies (Wang et al., 2016; Liu et al., 2019) . In hamsters SARS S protein based vaccine demonstrated ADE post-challenge but no such effect was observed in mice with S protein nanoparticle MERS vaccine following challenge dose (Roper and Rehm, 2009; Schindewolf and Menachery, 2019) . However, it not clear yet which particular domain and which key amino acids in S protein of SARS-CoV are involved in the above safety issues with S protein vaccines. Therefore, a more basic research need to be carried out on the structure and function of this protein and mutations can be introduced at places in this protein to eliminate such adverse effects . The deficiencies and inconsistencies in the results pertaining to lung pathology, liver damage, and ADE observed in CoV infections among animal models necessitates an improved understanding of the biological basis for their occurrence and a better knowledge of human immunology to avoid similar reactions in humans.

Vaccines are the most effective means to prevent and control infectious diseases economically (Remy et al., 2014) . In this pandemic all eyes are on the research institutions and the pharmaceutical companies involved in COVID-19 vaccine development. However, the vaccine production process has to follow the set stringent principles laid by various regulating agencies and a successful SARS-CoV-2 vaccine could not be achieved overnight. The biological characteristics of SARS-CoV-2 such as epidemiology, structural basis, pathogenesis, correlates of immunity, immune-pathologies, etc are still unclear . Generally, normal vaccine development takes a decade or two with very less success rate but there is a broad consensus between the scientists worldwide regarding the availability of vaccine against SARS-CoV-2 which is expected to be 12-18 moths away (Dresden, 2020). It is because the identification of SARS-CoV-2 was done within 3 months of its spread and the study of its other biological characteristics is undergoing very vigorously to develop the whole information which will potentially facilitate the rapid development of its vaccine. Globally, confirmed COVID-19 cases are still increasing at an alarming rate and it may potentially become a flu-like seasonal disease and remain in coexistence with human beings for a long time (Neher et al., 2020) . Thus, vaccine development is necessary even if it is occurring at a slower pace than the spreading of COVID-19 pandemic. Once a potential vaccine is announced by a researcher, a prospective producer pharmaceutical company has to submit an application to a regulatory authority such as Food and Drug Administration (FDA) for investigation of the new vaccine. The application must describe

This article is protected by copyright. All rights reserved the vaccine, its manufacturing process, its safety, and efficacy in animal testing (Dresden, 2020).

Broadly the vaccine production process can be classified into following stages (Ryan, 2020) : a) Vaccine design: A researcher studies the relevant pathogen characteristics, selects most suitable antigenic fragment, and makes that antigen get expressed preferably to get recognized by host immune system. b) Animal studies: The new proposed vaccine is tested in animal models to study immune responses, efficacy, and safety upon immunization. The correlates of immunity, immunopathologies, and level of protection conferred on challenge are also studied. f) Regulatory approval: The regulatory agency takes a final call regarding approval of the studied vaccine as a treatment option for the disease. Regulatory agency strictly carries out scrutiny of the evidences and the data on animal and human trials with the proposed vaccine to make a final decision on its suitability as a treatment option. Traditionally, it takes a decade or two for a new vaccine to go from a design to approval stage (Ryan, 2020) but the process of vaccine development against COVID-19 has briskly reached the phase II clinical trial at various places worldwide and it is expected to be the fastest vaccine ever produced in human history.

Because of structural similarity and binding to same host cell receptors, SARS-CoV-2 and SARS-CoV may potentially share similar disease pathogenesis and exhibit cross-immunity to some extent. The understanding of biological characteristics of SARS-CoV and technological advancement in vaccine production could make first-generation COVID-19 vaccine available very soon, though it may not be available to cater the current pandemic. There are about 7 or 8 SARS-CoV-2 antigenic candidates which could be employed for vaccine development. But there is a need of vigorous testing for immunogenicity, safety, efficacy, and level of protection conferred in the hosts. Hastening the deployment of first-generation vaccine for current pandemic could be

This article is protected by copyright. All rights reserved achieved by propelling the nucleic acid based priming vaccines followed by boosters of protein based vaccines to curtail the mortality in high risk groups such as elderly persons and health care workers. Parallel to this, more potent and efficient second-generation vaccine production for future should be carried out to prevent disease spread, mortalities, and viral shedding. Another intriguing aspect of CoVs is that in every decade of 21 st century there is a new major CoV epidemic viz. SARS in 2002, MERS in 2012, and now COVID-19 . Such epidemics are expected in future too. Among CoVs S2 subunit is highly conserved and homologous which is a potential target for development of a pan-CoV vaccines after enhancing its immunogenicity and it can be used across all population worldwide and against divergent strains of CoVs. Thus, there is a need to mobilize the international funding agencies to support the development, manufacture, and stockpiling of CoV vaccines.

Preliminary identification of potential vaccine targets for the COVID-19 Coronavirus (SARS-CoV-2) based on SARS-CoV immunological studies

The SARS-coronavirus papain-like protease: structure, function and inhibition by designed antiviral compounds

Presumed Asymptomatic Carrier Transmission of COVID-19

Coronavirus update: recent developments in vaccine research

Proposal for vaccination against SARS coronavirus using avian infectious bronchitis virus strain H from The Netherlands

Clinical characteristics of 24 asymptomatic infections with COVID-19 screened among close contacts in Nanjing, China

Clinical features of patients infected with 2019 novel coronavirus in

The continuing 2019-nCoV epidemic threat of novel coronaviruses to global health -The latest 2019 novel coronavirus outbreak in Wuhan

working on coronavirus vaccine. The pharma letter

Comparison of DNA and mRNA vaccines against cancer

SARS CoV subunit vaccine: antibody-mediated neutralisation and enhancement

The recombinant N-terminal domain of spike proteins is a potential vaccine against Middle East respiratory syndrome coronavirus (MERS-CoV) infection

Roadmap to developing a recombinant coronavirus S protein receptor-binding domain vaccine for severe acute respiratory syndrome

An emerging coronavirus causing pneumonia outbreak in Wuhan, China: calling for developing therapeutic and prophylactic strategies

Immunogenicity and protection efficacy of monomeric and trimeric recombinant SARS coronavirus spike protein subunit vaccine candidates

Research and Development on Therapeutic Agents and Vaccines for COVID-19 and Related Human Coronavirus Diseases

Improvement of Pharmacokinetic Profile of TRAIL via Trimer-Tag Enhances its Antitumor Activity in vivo

The membrane protein of severe acute respiratory syndrome coronavirus acts as a dominant immunogen revealed by a clustering region of novel functionally and structurally defined cytotoxic Tlymphocyte epitopes

Anti-spike IgG causes severe acute lung injury by skewing macrophage responses during acute SARS-CoV infection

A Comparison of Plasmid DNA and mRNA as Vaccine Technologies

Immunological characterizations of the nucleocapsid protein based SARS vaccine candidates

T-cell immunity of SARS-CoV: Implications for vaccine development against MERS-CoV

Profile of antibodies to the nucleocapsid protein of the severe acute respiratory syndrome (SARS)-associated coronavirus in probable SARS patients

The reproductive number of COVID-19 is higher compared to SARS coronavirus

Accepted Article This article is protected by copyright. All rights reserved

Live attenuated tularemia vaccines: Recent developments and future goals

The coronavirus nucleocapsid is a multifunctional protein

Live attenuated vaccines: Historical successes and current challenges

Learning from the past: possible urgent prevention and treatment options for severe acute respiratory infections caused by 2019-nCoV

Potential impact of seasonal forcing on a SARS-CoV-2 pandemic

A structural analysis of M protein in coronavirus assembly and morphology

Memory T cell responses targeting the SARS coronavirus persist up to 11 years postinfection

Understanding bat SARS-like coronaviruses for the preparation of future coronavirus outbreaks -Implications for coronavirus vaccine development

Severe acute respiratory syndrome coronavirus envelope protein ion channel activity promotes virus fitness and pathogenesis

Protective humoral responses to severe acute respiratory syndrome-associated coronavirus: Implications for the design of an effective protein-based vaccine

mRNA vaccines-A new era in vaccinology

Another decade, another coronavirus

Vaccines and global health: In search of a sustainable model for vaccine development and delivery

New vaccine technologies to combat outbreak situations

The economic value of vaccination: Why prevention is wealth

SARS vaccines: where are we? Expert Reviews of Vaccines

Transmission of 2019-nCoV infection from an asymptomatic contact in Germany

Coronavirus vaccines: Drug trials, chloroquine and treatments for COVID-19

Coronaviruses of domestic livestock and poultry: Interspecies transmission, pathogenesis and immunity

Vaccines for COVID-19: Perspectives, Prospects, and Challenges Based on Candidate SARS, MERS, and Animal Coronavirus Vaccines

Middle east respiratory syndrome vaccine candidates: cautious optimism

Recent developments for Pseudomonas vaccines

Epitope-based vaccine target screening against highly pathogenic MERS-CoV: an in silico approach applied to emerging infectious diseases

Codagenix raises $20 million for a new flu vaccine and other therapies

SARS vaccine protective in mice

Lack of peripheral memory B cell responses in recovered patients with severe acute respiratory syndrome: A six-year follow-up study

On the origin and continuing evolution of SARS-CoV-2

Potent binding of 2019 novel coronavirus spike protein by a SARS coronavirusspecific human monoclonal antibody

Gnotobiotic neonatal pig model of rotavirus infection and disease

Coronavirus disease (COVID-2019) R&D. Available at

Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation

Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation

Nowcasting and forecasting the potential domestic and international spread of the 2019-nCoV outbreak originating in Wuhan, China: A modelling study

Analysis of the genome sequence and prediction of B-cell epitopes of the envelope protein of Middle East respiratory syndrome-coronavirus

Patient-derived mutations impact pathogenicity of SARS-CoV-2

Measures for diagnosing and treating infections by a novel coronavirus responsible for a pneumonia outbreak originating in Wuhan

Decoding evolution and transmissions of novel pneumonia coronavirus (SARS-CoV-2) using the whole genomic data

The authors declare no conflict of interest of any kind arising out this manuscript

No ethical approval was required as this is a review article with no original research data.

Data sharing is not applicable to this article as no new data were created or analyzed in this study.

This article is protected by copyright. All rights reserved